Incident diabetes in course of antiretroviral therapy

Taramasso, Lucia; Squillace, Nicola; Ricci, Elena; Menzaghi, Barbara; Orofino, Giancarlo; Socio, Giuseppe Vittorio De; Molteni, Chiara; Martinelli, Canio; Madeddu, Giordano; Vichi, Francesca; Valsecchi, Laura; Celesia, Benedetto Maurizio; Maggi, Paolo; Rusconi, Stefano; Pellicanò, Giovanni Francesco; Sarchi, Eleonora; Gulminetti, Roberto; Falasca, Katia; Biagio, Antonio Di; Bonfanti, Paolo

doi:10.1097/qad.0000000000003548

Cited by 4 publications

(2 citation statements)

References 54 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The observed positive correlation between AST and ALT levels aligns with existing literature on liver function in HIV/AIDS patients [21; 22], indicating potential liver injury or inflammation. However, differences in enzyme elevation between INSTI-based and NNRTI-based ART regimens warrant further investigation [34]. The negative correlations between AST, ALT, and other liver markers, along with the varying associations of age and gender, contribute to our understanding of liver function in this population [26; 27].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Hepatic Toxicity Assessment in HIV’s Interaction with Reverse Transcriptase and Integrase Strand Transfer Inhibitors at a Military Hospital, Southsouth Nigeria

Odegbemi,

Olaniyan,

Muhibi

2024

Preprint

View full text Add to dashboard Cite

Anti-retroviral therapy (ART) use has made HIV a manageable condition, but there are risks associated with medications like Reverse Transcriptase Inhibitors (RTIs) and Integrase Strand Transfer Inhibitors (INSTIs), such as liver and renal toxicity. It is essential to understand these risks for effective treatment. Investigating liver toxicity related to RTIs and INSTIs in Nigeria is crucial for optimizing HIV treatment. This study aimed to assess the impact of Tenofovir Lamivudine Dolutegravir (TLD) on the liver function of HIV-patients at Nigerian Navy Hospital (NNH) Warri. Liver function of 170 participants was assessed, with 120 on ART and the remainder being HIV-negative attendees at NNH Warri. The study used a cross-sectional design and selected participants through simple random sampling. We collected data using semi-structured questionnaire. Blood samples were taken through venipuncture and stored at -20oC before analysis. Ethical approval was obtained, and data analysis was conducted using SPSS Statistical Software, with significance set at p < 0.05. The study found significant differences in AST, TP, Alb, and GST levels between HIV-positive subjects receiving TLD and HIV-negative individuals. HIV-positive subjects had lower AST and Alb levels but higher TP and GST levels. Further analysis revealed correlations between age, gender, and liver enzymes, highlighting the complex relationship between HIV, liver function, and treatment outcomes. The study suggests that decreased AST levels may have a protective effect, while ALT activity had minimal impact. Changes in TP, Alb, and GSTs emphasize the importance of monitoring hepatic synthetic function and detoxification pathways in HIV patients taking TLD.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Reverse Transcriptase Inhibitors and INSTI therapy benefits HIV clients, but metabolic syndrome and associated liver disease pose growing risks as HIV-positive individuals age [34].…”

Section: Discussionmentioning

confidence: 99%

Hepatic Toxicity Assessment in HIV’s Interaction with Reverse Transcriptase and Integrase Strand Transfer Inhibitors at a Military Hospital, Southsouth Nigeria

Odegbemi,

Olaniyan,

Muhibi

2024

Preprint

View full text Add to dashboard Cite

show abstract

Risk factors for progression from prediabetes to diabetes among older people with HIV

Masters,

Tassiopoulos,

Bao

et al. 2024

Aids

View full text Add to dashboard Cite

Objective: Risk factors for progression from prediabetes (pre-DM) to diabetes (DM) among people with HIV (PWH) receiving modern antiretroviral therapy (ART) require better characterization. Design: AIDS Clinical Trials Group (ACTG) A5322 (HAILO) was an observational cohort study of PWH ≥40 years old. Participants initiated ART through ACTG randomized clinical trials. Methods: We used Cox proportional hazards regression models to identify risk factors for development of DM among HAILO participants with pre-DM. Results: Among 1035 HAILO participants, 74 (7%) had pre-DM at entry and another 679 (66%) developed pre-DM during follow-up. Of 753 PWH with pre-DM, 167 (22%) developed DM. In multivariable models, the risk of developing DM was greater with higher BMI, lower CD4 count (≤200 cells/ mm3), hypertriglyceridemia, or higher waist circumference at pre-DM diagnosis (p < 0.01). Conclusion: Rates of pre-DM and progression to DM remain high among virally suppressed PWH receiving modern ART regimens. Traditional risks for DM, such as higher BMI or waist circumference, are associated with increased risk of incident DM among PWH with pre-DM. The association between lower CD4 and progression to DM suggests a role for advanced immunodeficiency and inflammation. Further investigation of interventions aimed at preventing DM among PWH with pre-DM is needed. Optimizing prevention and treatment for DM may be an intervenable opportunity to improve long-term outcomes for PWH.

show abstract

Metabolic effects of switching to Biktarvy (B/F/TAF) in patients with HIV‐1 treated with antiretroviral regimens that do not include tenofovir disoproxil fumarate (TDF) or tenofovir alafenamide (TAF): The Metabic study

Busca‐Arenzana,

Ortega‐González,

Díaz‐Almirón

et al. 2024

HIV Medicine

View full text Add to dashboard Cite

BackgroundStudies on switching to tenofovir alafenamide (TAF)‐based regimens raise concerns about a worse metabolic profile in people with HIV, even though most received tenofovir disoproxil fumarate (TDF) in their previous regimen. This study aims to evaluate changes in lipid fractions, glucose, and serum markers for hepatic steatosis (HS) after switching from a TDF‐ or TAF‐sparing regimen to bictegravir/emtricitabine/TAF (B/F/TAF).MethodsWe performed a retrospective cohort study of people with HIV who switched to B/F/TAF from TDF‐ or TAF‐sparing regimens between January 2019 and May 2022 with at least 6 months of follow‐up. The primary endpoint was the absolute change in lipid fractions at 6 months. Secondary outcomes were changes in lipid fractions at 12 months and changes in other metabolic parameters (glucose, creatinine, and HS based on the triglyceride‐to‐glucose [TyG] ratio at 6 and 12 months). Changes were analysed using mixed linear regression models with random intercept and time as a fixed effect.ResultsThe study included 259 people with HIV (median age 55 [interquartile range (IQR) 47–60] years; 80% male; 88% Caucasian; CD4+ T‐cell count 675 [IQR 450–880] cells/mm3; 84.3% HIV‐RNA <50 copies/mL). In total, 63 patients (30%) had hypertension, 93 (44%) dyslipidaemia, 30 (14%) diabetes, and 45% obesity/overweight. Most (60%) switched from integrase inhibitor‐based regimens, and 21% switched from a boosted regimen. At 6 months, significant reductions were observed in total cholesterol (−7.64 mg/dL [95% confidence interval (CI) −13.52 to −1.76; p = 0.002]), triglycerides (−23.4 [95% CI −42.07 to −4.65]; p = 0.003), and TyG ratio (−0.14 [95% CI −0.23 to −0.05]; p < 0.001).ConclusionIn our real‐life cohort, the effect of switching TDF‐/TAF‐sparing regimens to triple therapy with B/F/TAF improved total cholesterol, triglycerides, and serum markers of HS at 6 months and was neutral for the remaining metabolic parameters at 12 months.

show abstract

Incident diabetes in course of antiretroviral therapy

Cited by 4 publications

References 54 publications

Hepatic Toxicity Assessment in HIV’s Interaction with Reverse Transcriptase and Integrase Strand Transfer Inhibitors at a Military Hospital, Southsouth Nigeria

Hepatic Toxicity Assessment in HIV’s Interaction with Reverse Transcriptase and Integrase Strand Transfer Inhibitors at a Military Hospital, Southsouth Nigeria

Risk factors for progression from prediabetes to diabetes among older people with HIV

Metabolic effects of switching to Biktarvy (B/F/TAF) in patients with HIV‐1 treated with antiretroviral regimens that do not include tenofovir disoproxil fumarate (TDF) or tenofovir alafenamide (TAF): The Metabic study

Contact Info

Product

Resources

About